Molecure S.A. ('Molecure': WSE: MOC) a clinical stage biotechnology company using its world leading medicinal chemistry capabilities to discover first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases, announces agenda topics and participating key opinion leaders for its virtual R&D Day.
The webcast event will be hosted by Molecure on the 7th December 2022 at 13.30 - 16.30 CET / 12.30 - 15.30 BST/ 7.30 - 10.30 ET.
The presentations by Key Opinion Leaders and Molecure management will showcase the scientific insights and clear clinical needs that underpin Molecure's pipeline programs.
Agenda topics: 13.30-15.30
Molecure's Vision, Strategy and Pipeline
OATD-01, Molecure's first in class chitinase inhibitor: Clinical evaluation in sarcoidosis and potential patient impact (Prof. Krenke)
Landscape and therapy opportunity in sarcoidosis
Clinical development plan
Other opportunities in interstitial lung disease
OATD-02, Molecure's novel dual arginase inhibitor: o Pre-clinical activity in a broad range of cancers o State of oncology in Poland (Prof. Szczylik)
Clinical development plan 15.30-15.40 Break 15.40-16.30
Early-stage pipeline
Deubiquitinating enzymes (DUBs) program including USP7 in oncology
YKL40 in oncology
University of Michigan collaboration in fibrosis
mRNA platform
Key Opinion Leader Presenters: Rafal Krenke, Pulmonologist, Head of Department of Internal Medicine, Pulmonary Diseases & Allergy, Medical University of Warsaw
Cezary Szczylik, Oncologist, Head of the Department of Clinical Oncology and Chemotherapy Europejskie Centrum Zdrowia (European Health Center) Otwock
Molecure S.A. Presenters: Dr Marcin Szumowski - CEO, President of the Board
Dr Zbigniew Zasona - VP Research Biology, Member of the Board
Dr Samson Fung - Chief Medical Officer
Dr Nicolas Beuzen - Director of Business Development and Licensing
Contact:
Molecure S.A.
Tel: +(48) 728 728 143
Email: m.borkowska@molecure.com
About Molecure
Molecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate the function of underexplored protein and RNA targets to treat multiple incurable diseases.
Molecure has generated a diverse pipeline of eight distinct programs with the support of leading academic life science institutions globally, including Yale University, Rutgers University, the Flemish Institute for Biotechnology (VIB) in Ghent, the University of Michigan and the International Institute of Molecular and Cell Biology in Warsaw (IIMCB).
Molecure's most advanced in-house drug candidate is OATD-01, a first-in-class dual chitinase inhibitor for the treatment of interstitial lung diseases, such as sarcoidosis and idiopathic pulmonary fibrosis, that is Phase II ready. A Phase II trial in patients with sarcoidosis is expected to start in 2023.
Our second proprietary candidate is OATD-02, an oral, potent and selective first-in-class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer.
Molecure's headquarters and laboratories are located in Warsaw, Poland with an additional laboratory facility in od. The company is listed on the Warsaw Stock Exchange (ticker: MOC).
(C) 2022 Electronic News Publishing, source ENP Newswire